NCT01338987 · OUTCOME

Percentage of B Cells at One Year Post-transplant in Participants Who Did/Did Not Receive Leuprolide Following Bone Marrow Transplant (BMT)

Pilot Study of Leuprolide to Improve Immune Function After Allogeneic Bone Marrow Transplantation · Source last updated 2021-03-18

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure: MEDIAN
Unit: percentage of cells
Interval / dispersion: Full Range
Time frame: after first Bone Marrow Transplant, approximately 12 months post-transplant

What was measured

B cell percentage is defined as the percentage of lymphocytes that are B cells.

Analysis population: Only first BMT patients (SG1-3) with \>1 year of follow-up without relapse were evaluable. Of evaluable patients, 5 males and 9 females received and 7 males did not receive Lupron. Reasons for patients being inevaluable were missing data (2) or insufficient follow-up due to death without relapse (3), relapse (11), or withdrawal (1) before 1 year.

Groups in this outcome

Transplant Recipient

Patients receiving first allogeneic bone marrow transplant on this study.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

Group	Source count
Transplant Recipient	21

Reported measurements

Males that received leuprolide

Analysis denominator · Participants

Group	Source count
Transplant Recipient	5

Values in percentage of cells · Interval/dispersion: Full Range
Group	Value	Spread	Lower	Upper	Comment
Transplant Recipient	22.1	Not reported	2.2	30.7	Not reported

Males that did not receive leuprolide

Analysis denominator · Participants

Group	Source count
Transplant Recipient	7

Values in percentage of cells · Interval/dispersion: Full Range
Group	Value	Spread	Lower	Upper	Comment
Transplant Recipient	21.9	Not reported	0.2	32.5	Not reported

Females who all received leuprolide

Analysis denominator · Participants

Group	Source count
Transplant Recipient	9

Values in percentage of cells · Interval/dispersion: Full Range
Group	Value	Spread	Lower	Upper	Comment
Transplant Recipient	14.3	Not reported	2.1	50.5	Not reported

Complete source fields

classes

categories
measurements
group Id
OG000
lower Limit
2.2
upper Limit
30.7
value
22.1
denoms
counts
group Id
OG000
value
5
units
Participants
title
Males that received leuprolide
categories
measurements
group Id
OG000
lower Limit
0.2
upper Limit
32.5
value
21.9
denoms
counts
group Id
OG000
value
7
units
Participants
title
Males that did not receive leuprolide
categories
measurements
group Id
OG000
lower Limit
2.1
upper Limit
50.5
value
14.3
denoms
counts
group Id
OG000
value
9
units
Participants
title
Females who all received leuprolide

denoms

counts
group Id
OG000
value
21
units
Participants

description

B cell percentage is defined as the percentage of lymphocytes that are B cells.

dispersion Type

Full Range

groups

description
Patients receiving first allogeneic bone marrow transplant on this study.
id
OG000
title
Transplant Recipient

param Type

MEDIAN

population Description

Only first BMT patients (SG1-3) with \>1 year of follow-up without relapse were evaluable. Of evaluable patients, 5 males and 9 females received and 7 males did not receive Lupron. Reasons for patients being inevaluable were missing data (2) or insufficient follow-up due to death without relapse (3), relapse (11), or withdrawal (1) before 1 year.

reporting Status

POSTED

time Frame

after first Bone Marrow Transplant, approximately 12 months post-transplant

title

Percentage of B Cells at One Year Post-transplant in Participants Who Did/Did Not Receive Leuprolide Following Bone Marrow Transplant (BMT)

type

PRIMARY

unit Of Measure

percentage of cells

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice